Cart
sales@molnova.com
Isradipine
CAS No. 75695-93-1
Isradipine( PN 200-110 )
Catalog No. M15878 CAS No. 75695-93-1
Isradipine is a potent and selective L-type voltage-gated calcium channel blocker, used to treat high blood pressure.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 48 | In Stock |
|
| 5MG | 31 | In Stock |
|
| 10MG | 51 | In Stock |
|
| 25MG | 93 | In Stock |
|
| 50MG | 151 | In Stock |
|
| 100MG | 251 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 621 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameIsradipine
-
NoteResearch use only, not for human use.
-
Brief DescriptionIsradipine is a potent and selective L-type voltage-gated calcium channel blocker, used to treat high blood pressure.
-
DescriptionIsradipine is a potent and selective L-type voltage-gated calcium channel blocker, used to treat high blood pressure.(In Vitro):Isradipine has much higher (＞40 fold) affinity for Cav1.3 channels as well as good brain bioavailability. Isradipine has nearly equal potency at Cav1.2 and Cav1.3 channels.(In Vivo):Isradipine (0.1~3 mg/kg; p.o.) makes sodium excretion increase in a dose-dependent manner.Isradipine pre-treatment reduces 6-hydroxydopamine induced neurotoxicity at the striatal level. Protective effect of isradipine at the striatal level is dose-dependent as shown from 6 mice. Isradipine pre-treatment increases the number of surviving SNc DA cells after 6-hydroxydopamine induced degeneration. Isradipine is capable of protecting striatal dopaminergic terminals and SNc dopaminergic cell bodies against a slow, progressive insult created by intrastriatal injection of 6-hydroxydopamine.
-
In VitroIsradipine has much higher (＞40 fold) affinity for Cav1.3 channels as well as good brain bioavailability. Isradipine has nearly equal potency at Cav1.2 and Cav1.3 channels.
-
In VivoIsradipine (0.1~3 mg/kg; p.o.) makes sodium excretion increase in a dose-dependent manner.Isradipine pre-treatment reduces 6-hydroxydopamine induced neurotoxicity at the striatal level. Protective effect of isradipine at the striatal level is dose-dependent as shown from 6 mice. Isradipine pre-treatment increases the number of surviving SNc DA cells after 6-hydroxydopamine induced degeneration. Isradipine is capable of protecting striatal dopaminergic terminals and SNc dopaminergic cell bodies against a slow, progressive insult created by intrastriatal injection of 6-hydroxydopamine. Animal Model:Rats Dosage:0.1~3 mg/kg Administration:P.o.Result:Sodium excretion increased in a dose-dependent manner. ?
-
SynonymsPN 200-110
-
PathwayGPCR/G Protein
-
TargetCalcium Channel
-
RecptorCalcium Channel
-
Research AreaCardiovascular Disease
-
Indication——
Chemical Information
-
CAS Number75695-93-1
-
Formula Weight371.39
-
Molecular FormulaC19H21N3O5
-
Purity>98% (HPLC)
-
SolubilityEthanol: 74 mg/mL warmed (199.25 mM); DMSO: 74 mg/mL (199.25 mM)
-
SMILESCC1=C(C(OC)=O)C(C2=CC=CC3=NON=C32)C(C(OC(C)C)=O)=C(C)N1
-
Chemical Name3-isopropyl 5-methyl 4-(benzo[c][1,2,5]oxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Ilijic E, et al. Neurobiol Dis. 2011 Aug;43(2):364-7
molnova catalog
related products
-
Diltiazem
Diltiazem (CRD 401 free base) is an orally available L-type Ca2+ channel blocker with antihypertensive, antiarrhythmic, and cardioprotective properties that prevent post-reperfusion myocardial injury, angina pectoris, and cardiovascular-related diseases.
-
Calcium Channel anta...
Calcium Channel antagonist 3 is a voltage-gated calcium channel inhibitor (IC50 : 5-20 μM).
-
ORM-10103
ORM-10103 is a novel potent and selective inhibitor of the Na+/Ca2+ exchanger (NCX).
